Ipsen’s elafibranor has shown promise as a treatment for primary sclerosing cholangitis (PSC), a rare liver disease that ...

Researchers and clinicians have developed major new guidelines for the monitoring of patients with inflammatory bowel disease ...

Similar findings were seen in other biochemical liver ... primary sclerosing cholangitis (PSC) data demonstrates favorable safety profile and significant efficacy in second potential rare liver ...

Abstracts include a presidential plenary-selected Phase 2 study evaluating the combination of obeticholic acid and ...

Esperion announced the expansion of its development portfolio with a new program aimed at treating primary sclerosing cholangitis (PSC), a rare liver disease. The company confirmed the ...

About Primary Sclerosing Cholangitis Primary Sclerosing Cholangitis ... or interventional therapy to halt the progression of disease. A liver transplant is the only known long-term treatment ...

The global primary sclerosing cholangitis (PSC) market is on an impressive growth trajectory, with forecasts estimating a market valuation of USD 314.26 million by 2033. This robust expansion is ...

1 CCL24 blockade alters the proteomic profile of patients with primary sclerosing cholangitis and down-regulates central disease processes, T Snir, R Greenman, R Aricha, I Vaknin, M Frankel ...

Zurich (Switzerland), - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced ...

Primary Sclerosing Cholangitis (PSC) is a rare, progressive, cholestatic, immune‐mediated disease of the bile ducts. Bile ducts carry the digestive liquid bile from the liver to the small intestine.